Incidence and Risk Factors of Delayed Chemotherapy-Induced Nausea and Vomiting Among Adult Patients: A Cross-Sectional Study. [PDF]
Zheng M +9 more
europepmc +1 more source
Revisiting the Role of Lorazepam as an Adjunct in the Management of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Analysis. [PDF]
Peng TR, Lin HH, Wu TW, Hsu CY.
europepmc +1 more source
Fosnetupitant for long-delayed chemotherapy-induced nausea and vomiting in oxaliplatin-based regimens: a prospective observational study (LODEC-N). [PDF]
Iimura Y +9 more
europepmc +1 more source
Risk prediction models for chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. [PDF]
Xie X +5 more
europepmc +1 more source
Impact of Evolving Antiemetic Prophylaxis on Chemotherapy-Induced Nausea and Vomiting (CINV): A Five-Year Comparative Study in Sichuan, China (2018-2023). [PDF]
Xiong W +28 more
europepmc +1 more source
Patient-Controlled Real-Time Transcutaneous Electrical Acupoint Stimulation at Neiguan (PC6) for Chemotherapy-Induced Nausea and Vomiting in Breast Cancer: An Exploratory Single-Arm Two-Stage Trial. [PDF]
Liu H +11 more
europepmc +1 more source
Olanzapine (10 mg vs 5 mg vs 2.5 mg) for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) - a systematic review and network meta-analysis. [PDF]
Chow R +19 more
europepmc +1 more source
Acupuncture Therapies for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer: Protocol for a Systematic Review and Network Meta-Analysis. [PDF]
Luo Y, Bian Z, Wang Q, Lei T, Zhao H.
europepmc +1 more source
Palonosetron-loaded binary ethosome-incorporated transdermal gel: Formulation optimization, in vitro/in vivo evaluation, and therapeutic efficacy in chemotherapy-induced nausea and vomiting. [PDF]
Wang Q +7 more
europepmc +1 more source
Awareness of chemotherapy-induced nausea and vomiting and adherence to guidelines: results of a multinational and multicenter survey, part of the THRIVE program. [PDF]
Caponero R +4 more
europepmc +1 more source

